Arrowhead Pharmaceuticals adds Sarepta CEO Douglas Ingram to its board of directors
Arrowhead appointed Douglas Ingram, President and CEO of Sarepta Therapeutics, as a director effective February 6, 2025, under an Investor Rights Agreement with Sarepta. The filing ties the appointment to the Collaboration Agreement and Stock Purchase Agreement with Sarepta, which the filing says closed on February 7, 2025, and makes Mr. Ingram not independent under Nasdaq rules.
Key points
- Douglas Ingram appointed director effective February 6, 2025; appointment made under Investor Rights Agreement with Sarepta dated November 25, 2024
- Sign-on grant of restricted stock units valued at $771,200, scheduled to vest over three years
- Mr. Ingram is President and CEO of Sarepta; the Collaboration and Stock Purchase Agreements with Sarepta closed February 7, 2025
- Filing states Mr. Ingram is not considered an independent director under Nasdaq Listing Rules
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.